NG
VRTX icon

Norden Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Norden Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
3,542
-215
-6% -$95.3K 0.14% 130
2026
Q1 		$1.68M Buy
3,757
+389
+12% +$181K 0.16% 119
2025
Q4 		$1.53M Buy
3,368
+1,016
+43% +$438K 0.15% 121
2025
Q3 		$921K Sell
2,352
-223
-9% -$93.2K 0.09% 203
2025
Q2 		$1.15M Buy
2,575
+787
+44% +$363K 0.12% 161
2025
Q1 		$867K Sell
1,788
-60
-3% -$28K 0.1% 197
2024
Q4 		$744K Buy
1,848
+183
+11% +$84.8K 0.08% 251
2024
Q3 		$774K Buy
1,665
+286
+21% +$137K 0.09% 239
2024
Q2 		$646K Buy
1,379
+387
+39% +$168K 0.13% 171
2024
Q1 		$415K Buy
992
+377
+61% +$159K 0.08% 269
2023
Q4 		$250K Buy
+615
New +$227K 0.04% 232

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norden Group's VRTX Position: Q2 2026 in Review

Norden Group reduced its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q2 2026, selling an estimated $95.3K and leaving 3,542 shares worth $1.76M. The position accounts for 0.14% of the portfolio, ranked #130.

Norden Group first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Norden Group held 3,542 shares of Vertex Pharmaceuticals worth $1.76M as of Q2 2026.
  • Norden Group sold 215 Vertex Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
  • Vertex Pharmaceuticals made up 0.14% of Norden Group's portfolio in Q2 2026, its #130 holding.
  • Norden Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.